Personalised cancer vaccine cuts risk of disease returning by 42% in major trial

Trial: personalised vaccine cuts melanoma return risk

• A personalised cancer vaccine given alongside a widely used immunotherapy drug has cut the risk of patients dying or their skin cancer returning by 42% in a major clinical trial. • The approach is aimed at melanoma patients who have already had their tumour removed through surgery. • Around 1,100 patients were enrolled on the trial, among them Tony Chapman, 75, from Corby in the East Midlands, whose latest checks show he is cancer free three years after being told his melanoma had spread.